Biogen Shares Rise on Outlook for Alzheimer's Treatment

Biogen Idec reported positive interim results from an early-stage study of an Alzheimer’s disease drug, sending the company’s shares up more than 6% in Tuesday morning trading.



from WSJ.com: US Business http://ift.tt/11PfQ5p

via IFTTT